Loading
Search products, companies, tests, and guides — go from query to quote request in one place.
Tests
A proprietary enzyme-linked immunosorbent assay for quantitative detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein, including the receptor binding domain (RBD).
Indicators
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)
Tests
The determination of the amount of extracellular newly identified RAGE (receptor for advanced glycation end products) present in a sample.
Tests
The determination of the amount of fatty acid binding protein 4 in a sample.
Indicators
Fatty acid-binding protein, heart (133 aa, ~15 kDa) is encoded by the human FABP3 gene. This protein plays a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters.
Indicators
Galectin-3 (250 aa, ~26 kDa) is encoded by the human LGALS3 gene. This protein plays a role in both antibody-mediated immunity and carbohydrate binding.
Indicators
This gene is involved in erythropoiesis and transcriptional activation.
Indicators
This gene is involved in both DNA binding and transcriptional regulation.
Indicators
This gene plays a role in the modulation of transcription.
Tests
The determination of the amount of guanylate binding protein 1 present in a sample.
Tests
This test measures the amount of haptoglobin in your blood. Haptoglobin is a protein made by your liver to get rid of the hemoglobin outside your red blood cells.
Article
Research record from Talanta, 2026-03-05. PMID 41812402.
